Close×

De Bortoli Wines has won the International Wine and Spirits Competition’s inaugural Innovative Winery of the Year trophy for the closure on its new release Rosé Rosé wine, the first registered colour side-embossed screw cap in the world.

Working together with supplier Interpack, De Bortoli combined photographic printing, UV printing, and embossing to create the closure with its rose-inspired tattoo design. The label is then aligned with the rose on the cap during the bottling process.

Competition judges were impressed by the closure design and technology, citing it in their decision to give De Bortoli the gong. “De Bortoli have produced an integrated innovation, a visual tactile way of bringing the essence of what's in the bottle to the outside,” they said.

Leanne De Bortoli, who manages the family’s Yarra Valley estate in Victoria with winemaker husband Steve Webber, said the award acknowledged the winemaker’s commitment to innovation. “From our iconic Noble One, to igniting Australia’s love of pale, dry rosé with the Rosé Revolution, we are constantly exploring new and exciting wine styles; wines that will inspire our customers,” she said.

“The beautiful screw-cap for our new release Rosé Rosé is designed to grab your attention and leave a memorable impression.”

The family-owned company was the only Australian winery shortlisted for the award.

Food & Drink Business

Australia’s first social enterprise bakery, The Bread & Butter Project, has graduated its latest group of bakers, with its largest ever cohort marking the program’s 100th graduate.

The University of Sydney and Peking University have launched a Joint Centre for Food Security and Sustainable Agricultural Development, which will support research into improving the sustainability and security of food systems in Australia and China.

Sydney-based biotech company, All G, has secured regulatory approval in China to sell recombinant (made from microbes, not cows) lactoferrin. CEO Jan Pacas says All G is the first company in the world to receive the approval, and recombinant human lactoferrin is “next in line”.